Adagrasib(MRTX849)
Modify Date: 2024-01-09 19:11:58
Adagrasib(MRTX849) structure
|
Common Name | Adagrasib(MRTX849) | ||
|---|---|---|---|---|
| CAS Number | 2326521-71-3 | Molecular Weight | 604.12 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C32H35ClFN7O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Adagrasib(MRTX849)MRTX849 is a potent, orally-available, and mutation-selective covalent inhibitor of KRAS G12C with potential antineoplastic activity. MRTX849 covalently binds to KRAS G12C at the cysteine at residue 12, locks the protein in its inactive GDP-bound conformation, and inhibits KRAS-dependent signal transduction[1][2]. |
| Name | MRTX849 |
|---|
| Description | MRTX849 is a potent, orally-available, and mutation-selective covalent inhibitor of KRAS G12C with potential antineoplastic activity. MRTX849 covalently binds to KRAS G12C at the cysteine at residue 12, locks the protein in its inactive GDP-bound conformation, and inhibits KRAS-dependent signal transduction[1][2]. |
|---|---|
| Related Catalog | |
| Target |
KRAS G12C[1] |
| In Vitro | In cell lines, MRTX849 inhibits growth and viability of cells harboring KRASG12C mutations, but not in cells with other mutant forms or of wild-type KRAS[2]. |
| In Vivo | MRTX849 inhibits KRASG12C signaling in cell lines harboring this mutation, and results in tumor regression in a broad spectrum of KRASG12C animal models[2]. |
| References |
| Molecular Formula | C32H35ClFN7O2 |
|---|---|
| Molecular Weight | 604.12 |